8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Feb 20, 2026·SEC
Material company update
Jan 14, 2026·SEC
Oramed Pharmaceuticals Inc.(ORMP)Earnings, Financials & Key Ratios
ORMP•NASDAQ
2.6× P/E·Price updated Jun 19, 2026
AboutOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.Show more
- Revenue$2M
- EBITDA-$15M-18.9%
- Net Income$64M+435.3%
- EPS (Diluted)1.50+419.1%
- Gross Margin0.65%
- EBITDA Margin-748.35%
- Operating Margin-754.4%
- Net Margin3202.5%
- ROE37.12%+399.5%
ORMP Key Insights
Oramed Pharmaceuticals Inc. (ORMP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Healthy 5Y average net margin of 348.7%
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 5.9% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ORMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ORMP Price & Volume
Oramed Pharmaceuticals Inc. (ORMP) stock price & volume — 10-year historical chart
Loading chart...
ORMP Growth Metrics
Oramed Pharmaceuticals Inc. (ORMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.9%
3 Years-9.55%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM489.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM463.38%
Return on Capital
10 Years-25.61%
5 Years-17.1%
3 Years-8.72%
Last Year-8.35%
ORMP Recent Earnings
Oramed Pharmaceuticals Inc. (ORMP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (73%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 19, 2026Metric
Actual
Est
EPS
$0.16
—
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.06+25.0%
$0.08
Rev
—
$500,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.13+2925.0%
$0.04
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.05-25.0%
$0.04
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 19, 2026 | $0.16 | — |
| Q2 2026 | Mar 26, 2026 | $0.06vs $0.08+25.0% | —vs $500,000 |
| Q4 2025 | Nov 13, 2025 | $1.13vs $0.04+2925.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.05vs $0.04-25.0% | — |
Based on last 12 quarters of dataView full earnings history →
ORMP Peer Comparison
Oramed Pharmaceuticals Inc. (ORMP) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare ORMP vs Peers
Oramed Pharmaceuticals Inc. (ORMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ORMP Income Statement
Oramed Pharmaceuticals Inc. (ORMP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.46M | 2.45M | 2.7M | 2.71M | 2.7M | 2.7M | 1.34M | 0 | 2M | 0 |
Revenue Growth % | 283.15% | -0.29% | 10.37% | 0.26% | -0.26% | 0% | -50.43% | -100% | - | -100% |
Cost of Goods Sold | 187K | 86K | 90K | 90K | 0 | 0 | 0 | 193K | 1.99M | 31K |
COGS % of Revenue | 7.61% | 3.51% | 3.33% | 3.32% | - | - | - | - | 99.35% | - |
Gross Profit | 2.27M▲ 0% | 2.36M▲ 4.1% | 2.61M▲ 10.6% | 2.62M▲ 0.3% | 2.7M▲ 3.2% | 2.7M▲ 0.0% | 1.34M▼ 50.4% | -193K▼ 114.4% | 13K▲ 106.7% | -31K▲ 0% |
Gross Margin % | 92.39% | 96.49% | 96.67% | 96.68% | 100% | 100% | 100% | - | 0.65% | - |
Gross Profit Growth % | 1402.65% | 4.14% | 10.58% | 0.27% | 3.17% | 0% | -50.43% | -114.4% | 106.74% | - |
Operating Expenses | 13.04M | 16.06M | 17.24M | 14.47M | 26.93M | 43.3M | 17.11M | 12.78M | 15.1M | 14.22M |
OpEx % of Revenue | 530.94% | 655.86% | 637.96% | 533.84% | 996.15% | 1601.96% | 1276.79% | - | 755.05% | - |
Selling, General & Admin | 2.76M | 4.08M | 3.72M | 4.23M | 5.94M | 15.66M | 8.14M | 6.46M | 8.72M | 8.48M |
SG&A % of Revenue | 112.34% | 166.72% | 137.7% | 156.16% | 219.64% | 579.43% | 607.31% | - | 436% | - |
Research & Development | 10.28M | 11.98M | 13.52M | 10.23M | 20.99M | 27.64M | 8.97M | 6.32M | 6.38M | 5.77M |
R&D % of Revenue | 418.61% | 489.14% | 500.26% | 377.68% | 776.51% | 1022.53% | 669.48% | - | 319.05% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -31K |
Operating Income | -10.77M▲ 0% | -13.53M▼ 25.6% | -14.63M▼ 8.2% | -11.76M▲ 19.6% | -24.22M▼ 106.0% | -40.6M▼ 67.6% | -15.77M▲ 61.2% | -12.78M▲ 18.9% | -15.09M▼ 18.1% | -10.59M▲ 0% |
Operating Margin % | -438.56% | -552.35% | -541.29% | -433.84% | -896.15% | -1501.96% | -1176.79% | - | -754.4% | - |
Operating Income Growth % | -7.6% | -25.59% | -8.16% | 19.64% | -106.03% | -67.6% | 61.16% | 18.95% | -18.05% | - |
EBITDA | -10.77M | -13.52M | -14.62M | -11.75M | -24.15M | -36.98M | -15.57M | -12.59M | -14.97M | -10.5M |
EBITDA Margin % | -438.35% | -552.1% | -540.99% | -433.58% | -893.3% | -1367.96% | -1162.16% | - | -748.35% | - |
EBITDA Growth % | -7.6% | -25.59% | -8.15% | 19.65% | -105.5% | -53.14% | 57.88% | 19.17% | -18.9% | 25.83% |
D&A (Non-Cash Add-back) | 5K | 6K | 8K | 7K | 77K | 3.62M | 196K | 193K | 121K | 91K |
EBIT | -10.77M | -13.53M | 0 | 0 | 0 | -40.6M | 7.13M | -15.07M | 75.32M | 82.38M |
Net Interest Income | 779K | 897K | 1.06M | 690K | 341K | 3.57M | 4.45M | -853K | 2.37M | 15.88M |
Interest Income | 785K | 903K | 1.06M | 690K | 347K | 3.57M | 8.03M | 0 | 2.37M | 15.88M |
Interest Expense | 6K | 6K | 0 | 0 | 6K | 0 | 3.58M | 853K | 0 | 0 |
Other Income/Expense | -10K | -30K | -450K | -438K | 893K | 2.93M | 20.86M | -3.14M | 90.41M | 92.97M |
Pretax Income | -10.08M▲ 0% | -12.73M▼ 26.3% | -14.05M▼ 10.4% | -11.51M▲ 18.1% | -22.99M▼ 99.7% | -37.66M▼ 63.8% | 5.09M▲ 113.5% | -15.92M▼ 412.9% | 75.32M▲ 573.1% | 131.82M▲ 0% |
Pretax Margin % | -410.42% | -519.68% | -519.98% | -424.76% | -850.5% | -1393.41% | 379.7% | - | 3766.2% | - |
Income Tax | 400K | -800K | 300K | 192K | -2.88M | 100K | 0 | 3.18M | 11.31M | 21.85M |
Effective Tax Rate % | -3.97% | 6.29% | -2.13% | -1.67% | 12.52% | -0.27% | 0% | -19.99% | 15.01% | 16.58% |
Net Income | -10.48M▲ 0% | -12.73M▼ 21.4% | -14.36M▼ 12.8% | -11.51M▲ 19.8% | -22.24M▼ 93.2% | -37.76M▼ 69.8% | 5.53M▲ 114.6% | -19.1M▼ 445.8% | 64.05M▲ 435.3% | 110M▲ 0% |
Net Margin % | -426.71% | -519.68% | -531.08% | -424.76% | -822.72% | -1397.11% | 412.31% | - | 3202.5% | - |
Net Income Growth % | 4.41% | -21.44% | -12.79% | 19.81% | -93.19% | -69.82% | 114.63% | -445.76% | 435.29% | 489.55% |
Net Income (Continuing) | -10.48M | - | -14.36M | - | - | -37.76M | 5.09M | -19.1M | 64.02M | 109.97M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 744K | -656K | -928K | -918K | 0 | 0 |
EPS (Diluted) | -0.79▲ 0% | -0.86▼ 8.9% | -0.82▲ 4.7% | -0.56▲ 31.7% | -0.78▼ 39.3% | -0.97▼ 24.4% | 0.14▲ 114.4% | -0.47▼ 435.7% | 1.50▲ 419.1% | 2.62▲ 0% |
EPS Growth % | 9.2% | -8.86% | 4.65% | 31.71% | -39.29% | -24.36% | 114.43% | -435.71% | 419.15% | 463.38% |
EPS (Basic) | -0.79 | -0.86 | -0.82 | -0.56 | -0.78 | -0.97 | 0.14 | -0.47 | 1.53 | - |
Diluted Shares Outstanding | 13.31M | 14.88M | 17.45M | 20.53M | 28.47M | 39M | 40.57M | 40.83M | 42.42M | 41.97M |
Basic Shares Outstanding | 13.31M | 14.88M | 17.45M | 20.53M | 28.47M | 39M | 40.32M | 40.83M | 41.4M | 40.77M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ORMP Balance Sheet
Oramed Pharmaceuticals Inc. (ORMP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 20.3M | 31.04M | 33.32M | 40.51M | 95.34M | 157.11M | 162.58M | 143.22M | 133.27M | 68.15M |
Cash & Short-Term Investments | 20.12M | 30.46M | 32.28M | 39.9M | 94.14M | 155.72M | 162.05M | 141.93M | 125.89M | 65.84M |
Cash Only | 3.97M | 5M | 3.33M | 19.3M | 77.25M | 40.46M | 9.05M | 54.42M | 45.95M | 13.2M |
Short-Term Investments | 16.15M | 25.47M | 28.95M | 20.6M | 16.89M | 115.26M | 152.99M | 87.51M | 79.95M | 52.64M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.64M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | 846.07 | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 159K | 574K | 1.04M | 611K | 1.2M | 1.39M | 537K | 1.29M | 2.74M | 2.31M |
Total Non-Current Assets | 18.41M | 16.36M | 1.34M | 4.12M | 32.66M | 4.53M | 57.97M | 12.06M | 97.59M | 200.7M |
Property, Plant & Equipment | 18K | 17K | 24K | 174K | 932K | 1.81M | 1.57M | 1.11M | 1.34M | 1.25M |
Fixed Asset Turnover | 136.44x | 144.06x | 112.63x | 15.57x | 2.90x | 1.49x | 0.86x | - | 1.50x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 18.38M | 16.33M | 1.29M | 3.93M | 6.69M | 2.7M | 56.37M | 10.91M | 93.74M | 432.65M |
Other Non-Current Assets | 15K | 17K | 20K | 20K | 25.04M | 24K | 34K | 34K | 2.52M | 48K |
Total Assets | 38.71M▲ 0% | 47.4M▲ 22.4% | 34.66M▼ 26.9% | 44.63M▲ 28.8% | 128M▲ 186.8% | 161.64M▲ 26.3% | 220.55M▲ 36.4% | 155.28M▼ 29.6% | 230.86M▲ 48.7% | 268.85M▲ 0% |
Asset Turnover | 0.06x | 0.05x | 0.08x | 0.06x | 0.02x | 0.02x | 0.01x | - | 0.01x | 0.00x |
Asset Growth % | -9.61% | 22.43% | -26.87% | 28.76% | 186.78% | 26.28% | 36.44% | -29.6% | 48.68% | 152.23% |
Total Current Liabilities | 5.17M | 4.55M | 5.31M | 4.54M | 6.68M | 5.75M | 53.21M | 5.68M | 19.09M | 10.56M |
Accounts Payable | 571K | 1.14M | 1.34M | 594K | 2.61M | 2.17M | 551K | 789K | 443K | 481K |
Days Payables Outstanding | 1.11K | 4.82K | 5.42K | 2.41K | - | - | - | 1.49K | 81.38 | 6.47K |
Short-Term Debt | 0 | 0 | 0 | 44K | 130K | 247K | 51.01M | 0 | 0 | 268K |
Deferred Revenue (Current) | 2.45M | 2.45M | 2.7M | 2.7M | 2.7M | 1.34M | 0 | 0 | 1.35M | 5.05M |
Other Current Liabilities | 2.15M | 969K | 1.27M | 601K | -1.37M | -191K | 325K | 0 | 0 | 3.23M |
Current Ratio | 3.93x | 6.82x | 6.28x | 8.93x | 14.27x | 27.34x | 3.06x | 25.19x | 6.98x | 6.45x |
Quick Ratio | 3.93x | 6.82x | 6.28x | 8.93x | 14.27x | 27.34x | 3.06x | 25.19x | 6.98x | 6.45x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 14.31M | 11.73M | 9.96M | 7.22M | 4.8M | 4.74M | 4.44M | 4.25M | 12.03M | 20.01M |
Long-Term Debt | 18K | -7.82M | -5.63M | 31K | 403K | 647K | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 342K | 156K | 540K | 2.27M |
Deferred Tax Liabilities | 11K | 11K | 11K | 11K | 11K | 11K | 0 | 0 | 7.91M | 33.58M |
Other Non-Current Liabilities | 443K | 8.15M | 5.92M | 229K | 145K | 82K | 102K | 90K | 314K | 238K |
Total Liabilities | 19.47M | 16.29M | 15.27M | 11.75M | 11.48M | 10.49M | 57.66M | 9.93M | 31.12M | 30.57M |
Total Debt | 0 | 0 | 0 | 75K | 533K | 894K | 51.62M | 372K | 825K | 761K |
Net Debt | -3.97M | -5M | -3.33M | -19.22M | -76.71M | -39.57M | 42.57M | -54.05M | -45.12M | -12.44M |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.01x | 0.32x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.19x |
Interest Coverage | -1795.17x | -2254.50x | - | - | -4037.17x | - | 1.99x | -17.66x | - | - |
Total Equity | 19.24M▲ 0% | 31.11M▲ 61.7% | 19.39M▼ 37.7% | 32.88M▲ 69.5% | 116.52M▲ 254.4% | 151.16M▲ 29.7% | 162.89M▲ 7.8% | 145.35M▼ 10.8% | 199.74M▲ 37.4% | 238.28M▲ 0% |
Equity Growth % | -26.54% | 61.72% | -37.67% | 69.54% | 254.38% | 29.73% | 7.76% | -10.77% | 37.43% | 125.04% |
Book Value per Share | 1.45 | 2.09 | 1.11 | 1.60 | 4.09 | 3.88 | 4.02 | 3.56 | 4.71 | 5.68 |
Total Shareholders' Equity | 19.24M | 31.11M | 19.39M | 32.88M | 115.77M | 151.81M | 163.82M | 146.26M | 199.74M | 238.28M |
Common Stock | 163K | 207K | 208K | 284K | 424K | 476K | 485K | 480K | 472K | 491K |
Retained Earnings | -56.5M | -69.22M | -81.1M | -92.61M | -114.85M | -163.08M | -157.56M | -176.62M | -123.44M | -85.12M |
Treasury Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Accumulated OCI | 401K | 702K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 744K | -656K | -928K | -918K | 0 | 0 |
ORMP Cash Flow Statement
Oramed Pharmaceuticals Inc. (ORMP) cash flow — operating, investing & free cash flow history
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.83M | -14.66M | -12.94M | -12.44M | -21.18M | -28.7M | -10.29M | -8.41M | -9.14M | -8.94M |
Operating CF Margin % | -237.42% | -598.49% | -478.73% | -459.04% | -783.61% | -1061.82% | -768.28% | - | -457.25% | - |
Operating CF Growth % | -225.26% | -151.36% | 11.71% | 3.86% | -70.27% | -35.5% | 64.13% | 18.29% | -8.71% | -107.34% |
Net Income | -10.48M | -12.73M | -14.36M | -11.51M | -22.24M | -36.56M | 5.53M | -19.06M | 64.02M | 110M |
Depreciation & Amortization | 5K | 6K | 8K | 7K | 77K | 58K | 196K | 193K | 121K | 121K |
Stock-Based Compensation | 1.57M | 1.55M | 808K | 465K | 0 | 0 | 0 | 0 | 5.99M | 2.28M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.91M | -10K |
Other Non-Cash Items | 196K | 121K | 309K | 1.76M | 2.29M | 8.74M | -13.32M | 7.25M | -85.28M | -136.99M |
Working Capital Changes | 2.87M | -3.6M | 290K | -3.16M | -1.31M | -943K | -2.7M | 3.2M | -1.91M | 15.66M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.26M | -612K | 501K | -816K | 2.06M | -376K | -2.23M | 3.52M | 1.13M | 1.44M |
Cash from Investing | 4.3M | -7M | 11.26M | 4.63M | -22.26M | 30.21M | -73.04M | 105.82M | 5.44M | -37.34M |
Capital Expenditures | -7K | -5K | -15K | -82K | -375K | -496K | -254K | -18K | -1.93M | 192.68K |
CapEx % of Revenue | 0.29% | 0.2% | 0.55% | 3.03% | 13.87% | 18.35% | 18.96% | - | 96.65% | - |
Acquisitions | 0 | 0 | 0 | 0 | 1.5M | 24K | 0 | 0 | -7.25M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -3K | -2K | -4.24M | -999 | -1K | 2K | 0 | -60K | 6.25M | -14.15M |
Cash from Financing | 1.59M | 22.65M | 0 | 23.79M | 101.39M | 11.56M | 51.98M | -52.04M | -4.74M | -15.14M |
Debt Issued (Net) | - | - | - | - | - | - | 49.55M | -49.55M | 0 | -10.36M |
Equity Issued (Net) | 1.59M | 22.65M | - | 23.79M | 101.39M | 11.56M | 2.43M | -2.48M | -4.74M | -4.77M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.48M | -4.74M | -4.77M |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2K | 0 | 0 |
Net Change in Cash | 62K▲ 0% | 1.01M▲ 1530.6% | -1.67M▼ 264.9% | 15.97M▲ 1057.8% | 57.95M▲ 262.9% | -36.78M▼ 163.5% | -31.41M▲ 14.6% | 45.37M▲ 244.4% | -8.47M▼ 118.7% | -61.31M▲ 0% |
Free Cash Flow | -5.84M▲ 0% | -14.66M▼ 151.1% | -12.96M▲ 11.6% | -12.52M▲ 3.3% | -21.56M▼ 72.1% | -29.2M▼ 35.4% | -10.55M▲ 63.9% | -8.43M▲ 20.1% | -11.08M▼ 31.4% | -8.74M▲ 0% |
FCF Margin % | -237.7% | -598.69% | -479.28% | -462.07% | -797.48% | -1080.17% | -787.24% | - | -553.9% | - |
FCF Growth % | -225.66% | -151.15% | 11.64% | 3.34% | -72.15% | -35.45% | 63.87% | 20.09% | -31.41% | 16.51% |
FCF per Share | -0.44 | -0.99 | -0.74 | -0.61 | -0.76 | -0.75 | -0.26 | -0.21 | -0.26 | -0.21 |
FCF Conversion (FCF/Net Income) | 0.56x | 1.15x | 0.90x | 1.08x | 0.95x | 0.76x | -1.86x | 0.44x | -0.14x | -0.08x |
Interest Paid | - | - | - | - | - | - | 574K | 2.32M | 0 | 0 |
Taxes Paid | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
ORMP Key Ratios
Oramed Pharmaceuticals Inc. (ORMP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -46.14% | -50.55% | -56.85% | -44.04% | -29.77% | -28.22% | 3.52% | -12.39% | 37.12% | 55.42% |
Return on Invested Capital (ROIC) | -43.02% | -49.03% | -52.03% | -59.33% | -67.96% | -40.23% | -7.46% | -6.46% | -9.2% | -4.74% |
Gross Margin | 92.39% | 96.49% | 96.67% | 96.68% | 100% | 100% | 100% | - | 0.65% | - |
Net Margin | -426.71% | -519.68% | -531.08% | -424.76% | -822.72% | -1397.11% | 412.31% | - | 3202.5% | - |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.01x | 0.32x | 0.00x | 0.00x | 0.00x |
Interest Coverage | -1795.17x | -2254.50x | - | - | -4037.17x | - | 1.99x | -17.66x | - | - |
FCF Conversion | 0.56x | 1.15x | 0.90x | 1.08x | 0.95x | 0.76x | -1.86x | 0.44x | -0.14x | -0.08x |
Revenue Growth | 283.15% | -0.29% | 10.37% | 0.26% | -0.26% | 0% | -50.43% | -100% | - | -100% |
Related:ORMP Dividend History·ORMP Revenue History·ORMP Price History·ORMP P/E History·ORMP Financial Ratios·ORMP Institutional Holders
ORMP SEC Filings & Documents
Oramed Pharmaceuticals Inc. (ORMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ORMP Frequently Asked Questions
Oramed Pharmaceuticals Inc. (ORMP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in revenue for fiscal year 2025.
Oramed Pharmaceuticals Inc. (ORMP) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Oramed Pharmaceuticals Inc. (ORMP) is profitable, generating $110.0M in net income for fiscal year 2025 (3202.5% net margin).
Dividend & Returns
Oramed Pharmaceuticals Inc. (ORMP) has a return on equity (ROE) of 37.1%. This is excellent, indicating efficient use of shareholder capital.
Oramed Pharmaceuticals Inc. (ORMP) had negative free cash flow of $8.7M in fiscal year 2025, likely due to heavy capital investments.